Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Other financing activities (2016 - 2019)

Historic Other financing activities for Organogenesis Holdings (ORGO) over the last 4 years, with Q3 2019 value amounting to $924000.0.

  • Organogenesis Holdings' Other financing activities rose 56474.82% to $924000.0 in Q3 2019 from the same period last year, while for Sep 2019 it was $2.6 million, marking a year-over-year increase of 20673.46%. This contributed to the annual value of $5.7 million for FY2020, which is 9024.55% up from last year.
  • Latest data reveals that Organogenesis Holdings reported Other financing activities of $924000.0 as of Q3 2019, which was up 56474.82% from $849000.0 recorded in Q2 2019.
  • Organogenesis Holdings' Other financing activities' 5-year high stood at $924000.0 during Q3 2019, with a 5-year trough of $9000.0 in Q1 2018.
  • In the last 4 years, Organogenesis Holdings' Other financing activities had a median value of $427578.0 in 2017 and averaged $460891.0.
  • Its Other financing activities has fluctuated over the past 5 years, first tumbled by 9789.51% in 2018, then skyrocketed by 891111.11% in 2019.
  • Organogenesis Holdings' Other financing activities (Quarter) stood at $294019.0 in 2016, then soared by 94.69% to $572422.0 in 2017, then plummeted by 75.72% to $139000.0 in 2018, then soared by 564.75% to $924000.0 in 2019.
  • Its Other financing activities stands at $924000.0 for Q3 2019, versus $849000.0 for Q2 2019 and $811000.0 for Q1 2019.